查看文章

Alcohol use disorder is a leading cause of morbidity and mortality. 1–2 Alcohol consumption is related to approximately 4% of the global burden of disease. 1 In clinical settings and compared with the general population, the relative risk of mortality has been estimated to be 3· 38 for male patients and 4· 57 for female patients with alcohol use disorder. 2 Patients who reduce their alcohol consumption can halve this increased risk of mortality compared with patients with alcohol use disorder who do not. 3 However, the approved pharmacotherapies that could help patients with alcohol use disorder to achieve abstinence or reduce alcohol consumption are limited in number and efficacy. 4, 5 Therefore, there is an urgent need to develop more effective treatments in this area. Preclinical and human studies suggest that baclofen, a γ-aminobutyric-acid (GABA) B receptor agonist, might be a novel treatment for patients with …